Related Experiment Video
Updated: Sep 7, 2026
Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
Published on: July 10, 2012
Pediatric lung transplantation
1Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Insights
Pediatric lung transplantation offers survival benefits for children with end-stage lung disease. Personalized immunosuppression and early intervention are key to managing challenges like infections and chronic lung allograft dysfunction (CLAD).
Area of Science:
- Pediatric Pulmonology
- Transplantation Surgery
- Immunology
Background:
- Pediatric lung transplantation has evolved since the 1980s into an accepted therapy for end-stage pulmonary diseases in children.
- It offers selected pediatric patients significant survival benefits and improved quality of life.
- Over 100 pediatric lung transplants are performed globally each year.
Purpose of the Study:
- To review specific pediatric aspects of lung transplantation, including surgical challenges and immunosuppression effects on the developing immune system.
- To provide an update on managing pediatric lung transplant recipients and outline future challenges.
- To emphasize that children are not merely small adults in the context of transplantation.
Main Methods:
- Review of current literature and clinical practices in pediatric lung transplantation.
- Analysis of indications, surgical considerations, immunosuppression strategies, and infectious complications.
- Discussion of age-specific and regional variations in primary diagnoses for transplantation.
Main Results:
- Indications for pediatric lung transplantation differ from adults, with cystic fibrosis (CF) being common, but vary by age and region.
- Early referral, careful selection, and timely listing are critical for survival benefits.
- Immunosuppression side effects, particularly renal damage, are common; tailored, personalized therapy and therapeutic drug monitoring are essential.
Conclusions:
- Infectious complications are frequent, contributing to nearly 50% of deaths within the first year post-transplant.
- Chronic lung allograft dysfunction (CLAD) remains the primary barrier to long-term survival.
- Personalized immunosuppression strategies are vital to mitigate side effects and improve outcomes in pediatric lung transplant recipients.
Abstract:
Pediatric lung transplantation has been undertaken since the 1980s, and it is today considered an accepted therapy option in carefully selected children with end-stage pulmonary diseases, providing carefully selected children a net survival benefit and improved health-related quality of life. Nowadays, >100 pediatric lung transplants are done worldwide every year. Here, specific pediatric aspects of lung transplantation are reviewed such as the surgical challenge, effects of immunosuppression on the developing pediatric immune system, and typical infections of childhood, as it is vital to comprehend that children undergoing lung transplants present a real challenge as children are not 'just small adults'. Further, an update on the management of the pediatric lung transplant patient is provided in this review, and future challenges outlined. Indications for lung transplantation in children are different compared to adults, the most common being cystic fibrosis (CF). However, the primary diagnoses leading to pediatric lung transplantation vary considerably by age group. Furthermore, there are regional differences regarding the primary indication for lung transplantation in children. Overall, early referral, careful patient selection and appropriate timing of listing are crucial to achieve real survival benefit. Although allograft function is to be preserved, immunosuppressant-related side effects are common in children post-transplantation. Strategies need to be put into practice to reduce drug-related side effects through careful therapeutic drug monitoring and lowering of target levels of immunosuppression, to avoid acute-reversible and chronic-irreversible renal damage. Instead of a "one fits all approach", tailored immunosuppression and a personalized therapy is to be advocated, particularly in children. Further, infectious complications are a common in children of all ages, accounting for almost 50% of death in the first year post-transplantation. However, chronic lung allograft dysfunction (CLAD) remains the major obstacle for improved long-term survival.
